Lumata Health has announced that it raised $23 million in a Series B funding round, bringing its total funding to $36 million. The funding round was led by McKesson Ventures, LRVHealth, and Cencora Ventures, with participation from existing investors including Cortado Ventures.
The new funding will be used to further Lumata’s mission of eliminating preventable vision loss from conditions such as glaucoma, diabetic retinopathy, and age-related macular degeneration. Using predictive analysis and personalized interventions, Lumata’s platform is approaching systemic barriers head-on and proactively.
“We are thrilled to partner with investors who share our vision for a smarter, more effective approach to preventing blindness from chronic eye diseases,” said Lumata Health CEO Landon Grace following the funding round’s completion. “This investment will allow us to continue scaling our data-driven approach to ensuring access and adherence to vision-saving treatments for the millions of people in the US with these conditions.”
Michelle Snyder, Partner at McKesson Ventures, commented, “What impressed us most is Lumata’s potential to reduce overall healthcare costs while also generating significant value for ophthalmology practices.” She continued, “Their proactive, end-to-end solution not only improves patient outcomes, it creates a win-win scenario for everyone involved in the care continuum.”
Read the full press release here.